Elicio Therapeutics, Inc. (ELTX) earnings
ELTX earnings moved a median of -2.21% by the close. Quarterly and annual ELTX reports and results, each read against the price at its own news timestamp. Back to the ELTX overview →
19 measured ELTX earnings events.
Where these ELTX earnings landedvs 19 measured ELTX earnings reactions
| Middle 50% of ELTX earnings reactions | -10.15% to -0.53% |
|---|---|
| Median reaction (to close) | -2.21% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 ELTX earnings events with a measured close landed between -10.15% and -0.53%; 26% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Press release | -0.73% | -2.21% | |
| Form 10-Q Elicio Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.73% | -2.21% | |
| Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Press release | -2.37% | -12.16% | |
| Form 10-Q Elicio Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -2.37% | -12.16% | |
| Form 10-K/A Elicio Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.87% | +2.21% | |
| Form 10-K Elicio Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.22% | +7.96% | |
| Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | Press release | +0.00% | -1.60% | |
| Form 10-Q Elicio Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -1.60% | |
| Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates | Press release | +0.00% | -5.91% | |
| Form 10-Q Elicio Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -5.91% | |
| Form 10-K Elicio Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -2.94% | -17.65% | |
| Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | Press release | +4.04% | +4.81% | |
| Form 10-Q Elicio Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +4.04% | +4.81% | |
| Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates | Press release | — | -8.14% | |
| Form 10-Q Elicio Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | — | -8.14% | |
| Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates | Press release | -6.24% | -18.08% | |
| Form 10-Q Elicio Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -6.24% | -18.08% | |
| Form 10-K/A Elicio Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.55% | |
| Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates | Press release | +0.17% | -2.17% |
Keep exploring
More ELTX: analyst actions → · SEC filings → · ELTX overview →